查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
促红细胞生成素製剂市场规模,份额和趋势分析报告，按类型(生物製剂,生物仿製药),产品,应用(癌症,肾臟疾病,神经病学),地区,分部预测2023-2030
市场调查报告书
商品编码
1233158

促红细胞生成素製剂市场规模,份额和趋势分析报告，按类型(生物製剂,生物仿製药),产品,应用(癌症,肾臟疾病,神经病学),地区,分部预测2023-2030

Erythropoietin Drugs Market Size, Share & Trends Analysis Report By Type (Biologics, Biosimilars) By Product (Erythropoietin, Darbepoetin-alfa), By Application (Cancer, Renal Disease, Neurology), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 126 Pages | 商品交期: 2-10个工作天内

价格

促红细胞生成素製剂市场增长和趋势

Grand View Research, Inc. 的新报告预测全球促红细胞生成素市场规模将达到 78 亿美元，从 2023 年到 2030 年的复合年增长率为 1.5% 增长缓慢可归因于多项生物专利到期，生物仿製药的批准和采用增加，价格下降。

例如，PanGen Biotech Inc. 正在开发 Erisa (PDA10)。 这种促红细胞生成素生物仿製药正在进行 3 期临床试验，以确认其对贫血患者的安全性和有效性。

美国卫生与公众服务部开展了全国肾臟教育计划，以提高患者和医生对慢性肾脏病的认识。 肾臟是成人促红细胞生成素合成的唯一来源。 随着 CKD 的进展，肾臟质量减少，导致促红细胞生成素生成受损和贫血。 因此，提高患者和医生对疾病和可用 EPO 药物的认识有望推动市场。

亚太地区,非洲和中东地区对廉价 EPO 药物的需求不断增长，促使新进入者进入促红细胞生成素市场。 因此，一些主要参与者正在努力开发和商业化生物仿製药。 例如，Novotech (Australia) Pty Limited 有一种 EPO 生物类似药 efepoetin alfa，正在进行 3 期试验。

对 EPO 製剂安全性的担忧促使人们开发出治疗贫血的替代疗法。 例如，roxudustat (AstraZeneca) 和 daprodustat (GSK) 等 HIF-PH 抑製剂已在日本,中国和韩国获得批准。 2022 年 3 月，Zydus Lifesciences Ltd. 获得了印度药品监管局(DCGI)对 Oxemia(Desidustat)的批准。 它是可注射促红细胞生成素兴奋剂的替代品。 Oxemia 有可能解决未满足的医疗需求，因为它是印度首个用于治疗与慢性肾病相关的贫血的口服药物。 预计这些替代药物的批准将对市场增长产生负面影响。

促红细胞生成素製剂市场报告亮点

  • 按类型划分，生物製剂将在 2022 年占据最大的市场份额。 这可能是由于 FDA 批准的 EPO 生物製剂可用于治疗癌症特异性贫血和 CKD 患者。
  • 按产品划分，促红细胞生成素细分市场在 2022 年主导了 EPO 医药市场，原因是获批产品数量多且促红细胞生成素的处方率高。
  • 2022 年的 EPO 药物市场以肾病领域为主。 CKD 的高患病率和 EPO 药物的高处方率是该细分市场占据主导地位的主要因素。 根据国家肾臟基金会 (NKF) 的数据，全世界 10% 的人口患有慢性肾脏病 (CKD)。
  • 由于生物仿製药的审批延迟和市场渗透率低等因素，2022 年全球市场将由北美主导。

内容

第一章调查方法及范围

  • 市场细分和范围
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析(模型 1)
      • 方法 1:商品流方法
  • 调查假设
  • 二级信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场概况
  • 片段快照
  • 竞争格局快照

第 3 章促红细胞生成素药物市场变量,趋势和范围

  • 市场系列展望
    • 母公司市场展望
  • 类型渗透和增长前景图，2022 年
  • 市场动态
    • 市场驱动因素分析
      • 慢性病发病率增加
      • 标籤外使用红细胞生成刺激剂 (ESA)
    • 市场製约因素分析
      • 品牌药的专利到期
  • 市场分析工具
    • 行业分析:波特五力模型
      • 新进入者的威胁:中等
      • 买方的议价能力:正常
      • 竞争对手之间的敌意:高
      • 替代品威胁:高
      • 供应商的议价能力:低
    • 行业分析:Pestel
      • 政治与法律
      • 经济的
      • 技术
  • 管道分析

第 4 章促红细胞生成素市场:细分分析，按类型，2018-2030(百万美元)

  • 促红细胞生成素製剂市场:按类型的变化分析
    • 生物製剂
    • 生物仿製药

第 5 章促红细胞生成素药物市场:细分分析，副产品，2018-2030(百万美元)

  • 促红细胞生成素製剂市场:产品差异分析
    • 促红细胞生成素
    • 阿尔法达贝泊汀

第 6 章促红细胞生成素药物市场:细分分析，按应用，2018-2030(百万美元)

  • 促红细胞生成素製剂市场:应用的变化分析
    • 癌症
    • 肾臟疾病
    • 神经学
    • 其他

第 7 章促红细胞生成素产品市场:按类型,产品和应用分列的区域估计和趋势分析

  • 北美
    • SWOT 分析
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT 分析:
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 意大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT 分析
    • 日本
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 中国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 印度
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架和赎回方案
    • 泰国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架和赎回方案
    • 韩国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架和赎回方案
  • 拉丁美洲
    • SWOT 分析:
    • 巴西
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 墨西哥
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 中东和非洲 (MEA)
    • SWOT 分析:
    • 南非
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 沙特阿拉伯
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 科威特
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景

第八章竞争格局

  • 主要市场参与者的近期发展和影响分析
    • 新产品发布
    • 併购
    • 许可协议
    • 会议和活动
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商概况
    • 主要分销商和渠道合作伙伴列表
    • 主要客户
  • 上市公司
    • 2022 年主要参与者的市场份额分析
    • 公司市场分析
    • 热图分析
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 私人公司
    • 主要初创公司名单
    • 本地网络地图
  • 公司简介
    • 强生服务公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 诺华公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 梯瓦製药工业有限公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 安进公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • F. Hoffmann-La Roche Ltd.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • LG 化学
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 比奥康
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Intas Pharmaceuticals Ltd.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 太阳製药工业有限公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 雷迪博士实验室有限公司
      • 公司简介
      • 产品基准
      • 战略举措
Product Code: GVR-1-68038-861-9

Erythropoietin Drugs Market Growth & Trends:

The global erythropoietin drugs market size is expected to reach USD 7.8 billion expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc., The slow growth can be attributed to the patent expiry of multiple biologics, increasing approval and penetration of biosimilars, and declining prices. For instance, PanGen Biotech Inc. is developing Erisa (PDA10). This erythropoietin biosimilar drug is under phase 3 clinical trial to check the safety and efficacy of the drug in patients with anemia.

The U.S. Department of Health and Human Services runs the National Kidney Disease Education Program to raise awareness about chronic kidney disease conditions among patients and physicians. The kidney is the sole source of erythropoietin synthesis in adults. In progressive CKD, the kidney mass decreases, which results in the impairment of erythropoietin production, thereby causing anemia. Thus, the rising awareness about the disease and its available EPO medicines among patients and physicians is anticipated to drive the market.

Increasing demand for cheaper EPO drugs in Asia Pacific, Africa, and the Middle East has triggered the entry of new players in the erythropoietin drugs market. Thus, some of the key players are engaged in the development and commercialization of biosimilars. For instance, Novotech (Australia) Pty Limited has an EPO biosimilar, Efepoetin alfa in phase 3 trials.

Safety concerns with EPO agents have encouraged the development of alternative treatments for anemia. For instance, HIF-PH inhibitors such as roxudustat (AstraZeneca) and daprodustat (GSK) have been approved in Japan, China, and South Korea amongst others. In March 2022, Zydus Lifesciences Ltd. received approval for Oxemia (Desidustat) from the Drug Controller General of India (DCGI). It is an alternative to injectable erythropoietin-stimulating agents. Oxemia is a potential product, a first-of-its-kind oral treatment in India, for anemia associated with chronic kidney diseases, thereby solving unmet needs. The approval of these alternative drugs is expected to negatively impact market growth.

Erythropoietin Drugs Market Report Highlights:

  • By type, the biologics segment accounted for the largest share of the market in 2022. This can be attributed to the availability of FDA-approved EPO biologics for the treatment of cancer-induced anemia and CKD patients.
  • Based on product, the erythropoietin segment dominated the EPO drugs market in 2022 owing to the higher number of approved products and higher prescription rate of erythropoietin.
  • The renal diseases segment dominated the EPO drugs market in 2022. The high prevalence of CKD and the high prescription rate of EPO drugs are major factors contributing to the dominance of this segment. According to the National Kidney Foundation (NKF), 10% of the total population is affected by chronic kidney disease (CKD) worldwide.
  • North America dominated the global market in 2022 owing to factors such as late approval and lower penetration of biosimilars in the market

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Regional scope
    • 1.1.2 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Erythropoietin Drugs Market Variables, Trends, and Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Penetration and Growth Prospect Mapping for Type, 2022
  • 3.3 Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Increasing incidence of chronic diseases
      • 3.3.1.2 Off-label use of Erythropoiesis stimulating agents (ESAs)
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Patent expiration of branded drugs
  • 3.4 Market Analysis Tools
    • 3.4.1 Industry Analysis: Porter's Five Forces
      • 3.4.1.1 Threat of new entrants: Moderate
      • 3.4.1.2 Bargaining power of buyers: Moderate
      • 3.4.1.3 Competitive rivalry: High
      • 3.4.1.4 Threat of substitutes: High
      • 3.4.1.5 Bargaining power of suppliers: Low
    • 3.4.2 Industry Analysis: PESTEL
      • 3.4.2.1 Political & Legal
      • 3.4.2.2 Economical
      • 3.4.2.3 Technological
  • 3.5 Pipeline Analysis

Chapter 4 Erythropoietin Drugs Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)

  • 4.1 Erythropoietin Drugs Market: Type Movement Analysis
    • 4.1.1 Biologics
      • 4.1.1.1 Biologics Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 4.1.2 Biosimilars
      • 4.1.2.1 Biosimilars Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 5 Erythropoietin Drugs Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)

  • 5.1 Erythropoietin Drugs Market: Product Movement Analysis
    • 5.1.1 Erythropoietin
      • 5.1.1.1 Erythropoietin Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Darbepoetin-alfa
      • 5.1.2.1 Darbepoetin Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)

Chapter 6 Erythropoietin Drugs Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1 Erythropoietin Drugs Market: Application Movement Analysis
    • 6.1.1 Cancer
      • 6.1.1.1 Cancer Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
    • 6.1.2 Renal Diseases
      • 6.1.2.1 Renal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 6.1.3 Neurology
      • 6.1.3.1 Neurology Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 6.1.4 Others
      • 6.1.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 7 Erythropoietin Drugs Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

  • 7.1 North America
    • 7.1.1 SWOT Analysis
      • 7.1.1.1 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key Country Dynamics
      • 7.1.2.2 Target Disease Prevalence
      • 7.1.2.3 Competitive Scenario
      • 7.1.2.4 Regulatory Framework
      • 7.1.2.5 Reimbursement Scenario
      • 7.1.2.6 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Canada
      • 7.1.3.1 Key Country Dynamics
      • 7.1.3.2 Target Disease Prevalence
      • 7.1.3.3 Competitive Scenario
      • 7.1.3.4 Regulatory Framework
      • 7.1.3.5 Reimbursement Scenario
      • 7.1.3.6 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2 Europe
    • 7.2.1 SWOT Analysis:
      • 7.2.1.1 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 Germany
      • 7.2.2.1 Key Country Dynamics
      • 7.2.2.2 Target Disease Prevalence
      • 7.2.2.3 Competitive Scenario
      • 7.2.2.4 Regulatory Framework
      • 7.2.2.5 Reimbursement Scenario
      • 7.2.2.6 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 UK
      • 7.2.3.1 Key Country Dynamics
      • 7.2.3.2 Target Disease Prevalence
      • 7.2.3.3 Competitive Scenario
      • 7.2.3.4 Regulatory Framework
      • 7.2.3.5 Reimbursement Scenario
      • 7.2.3.6 UK Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4 France
      • 7.2.4.1 Key Country Dynamics
      • 7.2.4.2 Target Disease Prevalence
      • 7.2.4.3 Competitive Scenario
      • 7.2.4.4 Regulatory Framework
      • 7.2.4.5 Reimbursement Scenario
      • 7.2.4.6 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.5 Italy
      • 7.2.5.1 Key Country Dynamics
      • 7.2.5.2 Target Disease Prevalence
      • 7.2.5.3 Competitive Scenario
      • 7.2.5.4 Regulatory Framework
      • 7.2.5.5 Reimbursement Scenario
      • 7.2.5.6 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.6 Spain
      • 7.2.6.1 Key Country Dynamics
      • 7.2.6.2 Target Disease Prevalence
      • 7.2.6.3 Competitive Scenario
      • 7.2.6.4 Regulatory Framework
      • 7.2.6.5 Reimbursement Scenario
      • 7.2.6.6 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key Country Dynamics
      • 7.2.7.2 Target Disease Prevalence
      • 7.2.7.3 Competitive Scenario
      • 7.2.7.4 Regulatory Framework
      • 7.2.7.5 Reimbursement Scenario
      • 7.2.7.6 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key Country Dynamics
      • 7.2.8.2 Target Disease Prevalence
      • 7.2.8.3 Competitive Scenario
      • 7.2.8.4 Regulatory Framework
      • 7.2.8.5 Reimbursement Scenario
      • 7.2.8.6 Sweden Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Norway
      • 7.2.9.1 Key Country Dynamics
      • 7.2.9.2 Target Disease Prevalence
      • 7.2.9.3 Competitive Scenario
      • 7.2.9.4 Regulatory Framework
      • 7.2.9.5 Reimbursement Scenario
      • 7.2.9.6 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.9.7 Rest of Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3 Asia Pacific
    • 7.3.1 SWOT Analysis:
      • 7.3.1.1 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Japan
      • 7.3.2.1 Key Country Dynamics
      • 7.3.2.2 Target Disease Prevalence
      • 7.3.2.3 Competitive Scenario
      • 7.3.2.4 Regulatory Framework
      • 7.3.2.5 Reimbursement Scenario
      • 7.3.2.6 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 China
      • 7.3.3.1 Key Country Dynamics
      • 7.3.3.2 Target Disease Prevalence
      • 7.3.3.3 Competitive Scenario
      • 7.3.3.4 Regulatory Framework
      • 7.3.3.5 Reimbursement Scenario
      • 7.3.3.6 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 India
      • 7.3.4.1 Key Country Dynamics
      • 7.3.4.2 Target Disease Prevalence
      • 7.3.4.3 Competitive Scenario
      • 7.3.4.4 Regulatory Framework
      • 7.3.4.5 Reimbursement Scenario
      • 7.3.4.6 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 Australia
      • 7.3.5.1 Key Country Dynamics
      • 7.3.5.2 Target Disease Prevalence
      • 7.3.5.3 Competitive Scenario
      • 7.3.5.4 Regulatory Framework & Reimbursement Scenario
      • 7.3.5.5 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 Thailand
      • 7.3.6.1 Key Country Dynamics
      • 7.3.6.2 Target Disease Prevalence
      • 7.3.6.3 Competitive Scenario
      • 7.3.6.4 Regulatory Framework & Reimbursement Scenario
      • 7.3.6.5 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7 South Korea
      • 7.3.7.1 Key Country Dynamics
      • 7.3.7.2 Target Disease Prevalence
      • 7.3.7.3 Competitive Scenario
      • 7.3.7.4 Regulatory Framework & Reimbursement Scenario
      • 7.3.7.5 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.7.6 Rest of Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4 Latin America
    • 7.4.1 SWOT Analysis:
      • 7.4.1.1 Latin America Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Brazil
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Target Disease Prevalence
      • 7.4.2.3 Competitive Scenario
      • 7.4.2.4 Regulatory Framework
      • 7.4.2.5 Reimbursement Scenario
      • 7.4.2.6 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Mexico
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 Target Disease Prevalence
      • 7.4.3.3 Competitive Scenario
      • 7.4.3.4 Regulatory Framework
      • 7.4.3.5 Reimbursement Scenario
      • 7.4.3.6 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Argentina
      • 7.4.4.1 Key Country Dynamics
      • 7.4.4.2 Target Disease Prevalence
      • 7.4.4.3 Competitive Scenario
      • 7.4.4.4 Regulatory Framework
      • 7.4.4.5 Reimbursement Scenario
      • 7.4.4.6 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.4.7 Rest of Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Middle East & Africa (MEA)
    • 7.5.1 SWOT Analysis:
      • 7.5.1.1 Middle East & Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 South Africa
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Target Disease Prevalence
      • 7.5.2.3 Competitive Scenario
      • 7.5.2.4 Regulatory Framework
      • 7.5.2.5 Reimbursement Scenario
      • 7.5.2.6 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 Saudi Arabia
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Target Disease Prevalence
      • 7.5.3.3 Competitive Scenario
      • 7.5.3.4 Regulatory Framework
      • 7.5.3.5 Reimbursement Scenario
      • 7.5.3.6 Saudi Arabia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4 UAE
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Target Disease Prevalence
      • 7.5.4.3 Competitive Scenario
      • 7.5.4.4 Regulatory Framework
      • 7.5.4.5 Reimbursement Scenario
      • 7.5.4.6 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5 Kuwait
      • 7.5.5.1 Key Country Dynamics
      • 7.5.5.2 Target Disease Prevalence
      • 7.5.5.3 Competitive Scenario
      • 7.5.5.4 Regulatory Framework
      • 7.5.5.5 Reimbursement Scenario
      • 7.5.5.6 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.5.7 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 New Product Launch
    • 8.1.2 Merger and Acquisition
    • 8.1.3 Licensing Agreements
    • 8.1.4 Conferences and Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors and Channel Partners
    • 8.3.2 Key Customers
  • 8.4 Public Companies
    • 8.4.1 Key Company Market Share Analysis, 2022
    • 8.4.2 Company Market Position Analysis
    • 8.4.3 Heat Map Analysis
    • 8.4.4 Competitive Dashboard Analysis
      • 8.4.4.1 Market Differentiators
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
    • 8.5.2 Regional Network Map
  • 8.6 Company Profiles
    • 8.6.1. Johnson & Johnson Services, Inc.
      • 8.6.1.1 Company Overview
      • 8.6.1.2 Financial Performance
      • 8.6.1.3 Product Benchmarking
      • 8.6.1.4 Strategic Initiatives
    • 8.6.2 Novartis AG
      • 8.6.2.1 Company Overview
      • 8.6.2.2 Financial Performance
      • 8.6.2.3 Product Benchmarking
      • 8.6.2.4 Strategic Initiatives
    • 8.6.3 Teva Pharmaceutical Industries Ltd.
      • 8.6.3.1 Company Overview
      • 8.6.3.2 Financial Performance
      • 8.6.3.3 Product Benchmarking
      • 8.6.3.4 Strategic Initiatives
    • 8.6.4 Amgen, Inc.
      • 8.6.4.1 Company Overview
      • 8.6.4.2 Financial Performance
      • 8.6.4.3 Product Benchmarking
      • 8.6.4.4 Strategic Initiatives
    • 8.6.5 F. Hoffmann-La Roche Ltd.
      • 8.6.5.1 Company Overview
      • 8.6.5.2 Financial Performance
      • 8.6.5.3 Product Benchmarking
      • 8.6.5.4 Strategic Initiatives
    • 8.6.6 LG Chem
      • 8.6.6.1 Company Overview
      • 8.6.6.2 Financial Performance
      • 8.6.6.3 Product Benchmarking
      • 8.6.6.4 Strategic Initiatives
    • 8.6.7 Biocon
      • 8.6.7.1 Company Overview
      • 8.6.7.2 Financial Performance
      • 8.6.7.3 Product Benchmarking
      • 8.6.7.4 Strategic Initiatives
    • 8.6.8 Intas Pharmaceuticals Ltd.
      • 8.6.8.1 Company Overview
      • 8.6.8.2 Financial Performance
      • 8.6.8.3 Product Benchmarking
      • 8.6.8.4 Strategic Initiatives
    • 8.6.9 Sun Pharmaceutical Industries Ltd.
      • 8.6.8.1 Company Overview
      • 8.6.9.2 Financial Performance
      • 8.6.9.3 Product Benchmarking
      • 8.6.9.4 Strategic Initiatives
    • 8.6.10 Dr. Reddy's Laboratories Ltd
      • 8.6.10.1 Company Overview
      • 8.6.10.2 Product Benchmarking
      • 8.6.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Erythropoietin Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 7 Global Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 8 North America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 10 North America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 11 North America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 U.S. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 17 Canada Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 21 Europe Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 22 Germany Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 23 Germany Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 24 Germany Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 25 U.K. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 U.K. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 U.K. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 France Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 29 France Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 30 France Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 31 Italy Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 33 Italy Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 34 Spain Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 36 Spain Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 37 Denmark Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Denmark Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 40 Sweden Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 42 Sweden Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 43 Norway Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 45 Norway Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 50 Japan Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 52 Japan Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 53 China Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 China Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 55 China Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 56 India Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 India Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 58 India Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 59 South Korea Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 61 South Korea Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 62 Australia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 Australia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 65 Thailand Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 67 Thailand Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 68 Latin America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 71 Latin America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 72 Brazil Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 74 Brazil Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 75 Mexico Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 77 Mexico Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 80 Argentina Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 88 South Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 90 South Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 91 UAE Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 93 UAE Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Erythropoietin drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value - chain - based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (By type, by product, and by application)
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Penetration & growth prospect mapping for type, 2022
  • Fig. 13 Market driver relevance analysis (Current & future impact)
  • Fig. 14 Market restraint relevance analysis (Current & future impact)
  • Fig. 15 Erythropoietin drugs market: Type outlook and key takeaways
  • Fig. 16 Erythropoietin drugs market: Type movement analysis
  • Fig. 17 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Erythropoietin drugs market: Product outlook and key takeaways
  • Fig. 20 Erythropoietin drugs market: Product movement analysis
  • Fig. 21 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Darbepoetin - alfa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Erythropoietin drugs market: Application outlook and key takeaways
  • Fig. 24 Erythropoietin drugs market: Application movement analysis
  • Fig. 25 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Renal diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America: SWOT analysis
  • Fig. 31 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Key Country Dynamics
  • Fig. 33 U.S. Target Disease Prevalence
  • Fig. 34 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Key Country Dynamics
  • Fig. 36 Canada Target Disease Prevalence
  • Fig. 37 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe: SWOT analysis
  • Fig. 39 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Key Country Dynamics
  • Fig. 41 Germany Target Disease Prevalence
  • Fig. 42 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 U.K. Key Country Dynamics
  • Fig. 44 U.K. Target Disease Prevalence
  • Fig. 45 U.K. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France Key Country Dynamics
  • Fig. 47 France Target Disease Prevalence
  • Fig. 48 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy Target Disease Prevalence
  • Fig. 51 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain Key Country Dynamics
  • Fig. 53 Spain Target Disease Prevalence
  • Fig. 54 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark Key Country Dynamics
  • Fig. 56 Denmark Target Disease Prevalence
  • Fig. 57 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden Key Country Dynamics
  • Fig. 59 Sweden Target Disease Prevalence
  • Fig. 60 Sweden Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Norway Key Country Dynamics
  • Fig. 62 Norway Target Disease Prevalence
  • Fig. 63 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Rest of Europe Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific: SWOT Analysis
  • Fig. 66 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Japan Key Country Dynamics
  • Fig. 68 Japan Target Disease Prevalence
  • Fig. 69 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 China Key Country Dynamics
  • Fig. 71 China Target Disease Prevalence
  • Fig. 72 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 India Key Country Dynamics
  • Fig. 74 India Target Disease Prevalence
  • Fig. 75 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia Key Country Dynamics
  • Fig. 77 Australia Target Disease Prevalence
  • Fig. 78 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea Key Country Dynamics
  • Fig. 80 South Korea Target Disease Prevalence
  • Fig. 81 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Thailand Key Country Dynamics
  • Fig. 83 Thailand Target Disease Prevalence
  • Fig. 84 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Rest of APAC Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Latin America (LATAM): SWOT Analysis
  • Fig. 87 Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Brazil Key Country Dynamics
  • Fig. 89 Brazil Target Disease Prevalence
  • Fig. 90 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Mexico Key Country Dynamics
  • Fig. 92 Mexico Target Disease Prevalence
  • Fig. 93 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Argentina Key Country Dynamics
  • Fig. 95 Argentina Target Disease Prevalence
  • Fig. 96 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Rest of LATAM Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Middle East & Africa (MEA): SWOT Analysis
  • Fig. 99 Middle East & Africa (MEA) Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 South Africa Key Country Dynamics
  • Fig. 101 Target Disease Prevalence
  • Fig. 102 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Saudi Arabia Key country dynamics
  • Fig. 104 Saudi Arabia Target Disease Prevalence
  • Fig. 105 Saudi Arabia Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 UAE Key Country Dynamics
  • Fig. 107 UAE Target Disease Prevalence
  • Fig. 108 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Kuwait Key Country Dynamics
  • Fig. 110 Kuwait Target Disease Prevalence
  • Fig. 111 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Heat Map Analysis
  • Fig. 114 Strategic Framework